Searched for
RIVASTIGMINE
China halts sale of Sun Pharma drug used to treat dementiaChina's medicine regulator has halted the import, sale, and use of Sun Pharmaceutical Industries' dementia drug, rivastigmine hydrogen tart...- US generics business to continue its growth momentum: Pharma firm Cadila HealthcareAccording to the Cadila Healthcare's annual report for fiscal year 2019-20, the company is planning to introduce additional "topical, trans...
- Cadila Healthcare gains on USFDA nod for memory loss drugThe group now has 252 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.
- Alzheimer’s can occur in 30s & 40s: Common signs include repeating questions, becoming suspicious of othersResearch shows that damage to the brain starts years before the symptoms appear.
- Aurobindo Pharma gets final USFDA nod for dementia drugDrug firm Aurobindo Pharma has received final approval from USFDA to manufacture and market Rivastigmine Tartrate Capsules USP.
- Orchid Pharma gets final nod from USFDA for Parkinson's drugChennai-based Orchid Pharma has received final approval from the US health regulator for its generic version of rasagiline tablets.
- Dr Reddy's recalls Rivastigmine Tartrate capsules of 1.5 mg strength from USDr Reddy's Laboratories (DRL) has initiated voluntary recall of Rivastigmine Tartrate Capsules of 1.5 mg strength from the USA market.
- Orchid Chemicals surges 16% on USFDA approval for Gemifloxacin MesylateThe company is present in segments like anti-infective, anti-inflammatory, central nervous system, cardio vascular segment and other oral a...
- Twelve stocks in focus in Monday's tradeIndian markets are expected to trade in a range. Here is a list of twelve stocks which are likely to remain in focus today.
- Orchid Chemicals gets USFDA nod for two generic drugsThe nod was for generic Rivastigmine capsules and Felodipine extended release tablets aimed at treating mild to moderate dementia and hyper...
- Alembic Pharmaceuticals soars on patent settlement case with NovartisShares of Alembic Pharma surged by over 4% after the co said it along with Breckenridge Pharma Inc, USA has settled a patent case with Nova...
- Dr Reddy's expects North American biz to drive growth this FYDr Reddy's Laboratories expects generics business in North America to be its main growth driver this fiscal.
- STCI puts buy on Sun Pharma; target Rs 1,732STCI Capital Markets has initiated ‘buy’ on Sun Pharmaceuticals for a 12 month target price of Rs1,732.
- Indian generic companies may tread Ranbaxy pathRanbaxy's patent settlement with Pfizer may lead more Indian generic cos to go for out-of-court settlements with their innovator counterpar...
- DRL, Novartis smoke peace pipe on Alzheimer's drugDr Reddy’s Laboratories (DRL) has entered a settlement agreement with Novartis Pharma to suspend the launch of its generic capsule rivastig...
- Sun settles patent row with NovartisSun Pharmaceutical Industries has reached an out-of-court settlement with Novartis in the United States with regard to a patent dispute ove...
- Sun, Novartis settle Exelon drug disputeSun Pharmaceutical has reached an out-of-court settlement with Novartis in the US with regard to a patent dispute over the Swiss drug major...
- Stocks to watch on ThursdayShares of airline companies are likely to see some pressure as the government has asked airlines to come clean on the tax component.
- Sun Pharma gets US nod for Novartis' ExelonSun Pharma said it has won a 180-day marketing exclusivity for its version of Novartis' $200-million drug Exelon in the US.
- DRL gets tentative USFDA nod for Alzheimer's drugDr Reddy's Laboratories Ltd has received tentative approval from the USFDA for the drug 'Rivastigmine' in capsule form.
Load More
